What's Happening?
Acurex Biosciences, a biotechnology company, has been awarded a grant from Aligning Science Across Parkinson’s (ASAP) in collaboration with The Michael J. Fox Foundation for Parkinson’s Research. This grant will support a multi-year collaboration led
by Professor Tim Greenamyre of the University of Pittsburgh, alongside researchers from King’s College London and the University of Pittsburgh. The team will join the Collaborative Research Network to address critical research questions about Parkinson’s disease. Acurex is focusing on a novel approach targeting the enzyme 15-lipoxygenase (15-LO), which is believed to contribute to the loss of dopamine-producing brain cells in Parkinson’s disease. By inhibiting 15-LO, Acurex aims to protect nerve cells and develop treatments that go beyond symptom management.
Why It's Important?
The grant represents a significant step forward in Parkinson’s disease research, which affects nearly 10 million people globally. Current treatments primarily manage symptoms without halting disease progression. Acurex’s approach could lead to groundbreaking therapies that address the underlying causes of Parkinson’s, potentially altering the disease's trajectory. This development is crucial for patients seeking more effective treatments and could influence future research directions in neurodegenerative diseases. The collaboration with leading researchers and institutions underscores the potential impact of this research on the medical community and patients worldwide.
What's Next?
Acurex and its partners will work to define the role of 15-LO in Parkinson’s disease and advance their lead drug candidates toward human clinical trials. The company is preparing to raise Series A funding to support these efforts. The success of this research could pave the way for new therapeutic strategies and enhance understanding of neurodegenerative disorders, potentially leading to broader applications in related diseases.
